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Abstract
Tamoxifen (TAM) is used widely for treatment and prevention of breast cancer.
However, TAM has been reported to have a negative effect on glutathione (GSH) levels
and 8-hydroxydeoxyguanosine (8-OHdG). Thymoquinone (TQ), the main active
ingredient of Nigella sativa, or Black seeds, is used in the Middle East for treatment of
several diseases, especially cancer. The aim of my research was to investigate the role of
thymoquinone in improving 8-OHdG and GSH compared with tamoxifen in female
Sprague Dawley rats treated with 7,12 dimethylbenz (a)anthracene (DMBA, a drug that
induces mammary cancer). 8-OHdG is the most commonly assayed fingerprint of free
radical attack on DNA and is involved in tumor progression. Five groups of 10 rats
(Controls, DMBA, TAM, TQ, and TAM+TQ) were treated for 10 weeks after injection of
DMBA. Tumors were found in only two DMBA treated rats. However, there was a
coloration observed in the mammary glands in another four of the DMBA treated rats.
There were no mammary gland changes in the other four groups. 8-OHdG in blood
samples was significantly higher in the TAM group compared with the TQ (P <0.001),
the controls (P= 0.008) and the DMBA (P=0.041) treated groups. TQ significantly
decreased 8-OHdG by itself compared with DMBA (P= 0.039) and TAM, but did not
significantly reduce the effect of TAM in the TAM+TQ group. On the other hand, GSH
did not differ among treatments. The data for body weight gain over 12 weeks showed a
significant difference among the groups (P<0.001). The TAM and TAM+TQ groups had
the lowest weight gain compared with the TQ, the control and the DMBA (P<0.01)
treated groups. I conclude that TQ could be a better anticancer drug than TAM because it
decreased 8-OHdG and protected growth.
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Introduction
•

Cancer

Cancer is one of the most severe diseases that affect people around the world. This
disease is reported to be the second most common cause of death in the United States
(Soujanya et al, 2011). Cancer occurs when cell division is out of control and cells divide
quickly. This quick division creates a tumor which blocks or invades normal tissues.

According to American Cancer Society one in eight women will develop invasive
breast cancer. Breast cancer occurs when cells grow and multiply in uncontrolled way in
breast tissue (Figure 1).
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Figure 1: Loss of normal growth control in cancer cells

Tamoxifen (TAM) is a drug used currently for treatment and prevention of breast
cancer. Herbs also sometimes are used for prevention and as a cure of cancer.
Thymoquinone (TQ), the main active ingredient of Nigella sativa, or Black seeds, is used
in the Middle East for treatment of several diseases, especially cancer. The purpose of my
study was to compare TAM and TQ.

•

Tamoxifen (TAM)

In the early 1970s, the first study of a new antiestrogen called tamoxifen (TAM, ICI
46474) in breast cancer patients was published (Cole et al., 1971). In 1990, TAM was
approved by the United States Food and Drug Administration (FDA). TAM citrate, a
derivative of triphenylethylene (Curtis, 2001), is now frequently prescribed, and
compelling data have demonstrated a significant overall survival benefit with the
administration of this drug in breast cancer patients with endocrine responsive disease
(EBCTCG, 1998; Clarke, 2003). Several TAM derivatives are now available, including
toremifene (chloro-tamoxifen) and droloxifene (3- hydroxytamoxifen). Not surprisingly,
both drugs are essentially equivalent to TAM in terms of their antitumor activities and
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toxicities (Roos et al., 1983; Pyrhonen et al., 1999), so neither is widely used in clinical
practice.

TAM is the most widely prescribed Selective Estrogen Receptor Modulator. SERMs,
also called antiestrogens, compete with estrogens for binding to the Estrogen Receptor
(ER). ERs bind estrogen as well as other agonists or antagonists. The first form of ER
identified was ER α. Its activity is influenced by coactivator and corepressor proteins that
can either positively or negatively modulate ERα-mediated transcriptional activity
(Dobrzycka et al., 2003). The more recently discovered form is ER β which is encoded by
a different gene. Target cells for estrogen action may contain varying concentrations of
homodimers of one or both ERs (Gennari et al., 2007). ER α and β are different in their
structure and location. For example, ER α is documented to be found in breast cancer
cells (Yaghmaie et al., 2005), while ER β is found in the heart and kidney (Babiker et al.,
2002). Thus, different ERs have different responses to a SERM.

The clinical response to antiestrogens may be affected by exogenous estrogenic
exposures. These exposures include estrogenic hormone replacement therapies, as well as
dietary or environmental exposures that directly or indirectly increase a tissue’s
estrogenic environment (Clarke et al., 2003). However, SERMs were given their name
because of their unique pharmacologic properties (Gennari et al., 2007). SERMs can treat
and prevent breast cancer by interacting with intracellular estrogen receptors in target
organs as estrogen receptor agonists and antagonists. SERMs can achieve the beneficial
effects of estrogens in nonmammary tissues such as bone, but have an estrogen
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antagonistic effect in mammary tissue (Curtis, 2001). SERMs act by binding to the ER,
inducing a characteristic conformational change that enables its interaction with specific
DNA sequences in the regulatory regions of target gene promoters (Haynes and Dowsett,
1999). SERMs induce a conformational change within the ER that is different from that
caused by estradiol, the main naturally occurring estrogen, and this leads to differential
recognition of the specific ligand-receptor complexes by the cellular transcriptional
machinery (McDonnell et al., 1995; Beekman et al., 1993).

The Early Breast Cancer Trialists’ Collaborative Group tested TAM on more than
37,000 women in 55 separate randomized trials prior to 1990. The group found that TAM
significantly reduced cancer recurrence in women with estrogen receptor positive tumors
after 5 years of treatment (Early Breast Cancer Trialists’ Collaborative Group, 1998).
According to the findings from the international ATLAS (Adjuvant Tamoxifen, Longer
Against Shorter) study, ten years of treatment with tamoxifen was significantly better
than the standard 5 years in reducing the risk for breast cancer recurrence (Mulcahy,
2012) .American Cancer Society reported that 75% of all breast cancers are ER positive
(ER+). They grow in response to the hormone estrogen (Early Breast Cancer Trialists’
Collaborative Group, 1998).

In a placebo-controlled trial performed in the US, the National Surgical Adjuvant
Breast and Bowel Project (NSABP)-P1 trial tested 13,388 women at high risk for
developing breast cancer who were treated with TAM (20 mg/day) for a 55 month
follow-up trial. In this trial they found that TAM decreased the risk of invasive and non-
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invasive breast cancers in all age groups by nearly 50% and decreased the incidence of
ER positive breast cancer risk by 69% (Fisher et al., 1998; Curtis, 2001).

When compared with cytotoxic chemotherapy, antiestrogens have a low incidence of
serious side effects and are associated with mostly minor toxicities. Three large,
randomized, chemoprevention studies with TAM have been conducted: the NSABP P-1
trial (n=13,388 participants) (Fisher et al., 1998), the Royal Marsden Trial (n=2471
participants) (Powles et al., 1998), and the Italian Chemoprevention Trial (n=5408
participants) (Veronesi et al., 1998). The Italian Trial reported that TAM decreased the
breast cancer risk by 82% among women at high risk for ER+ breast cancer (Veronesi et
al., 2003). In the NSABP trial, a decreased breast tumor incidence was seen only for ER+
tumors (Fisher et al., 1998). The P-1 trial reported a significant decrease in the incidence
of both noninvasive (50%) and invasive (49%) breast cancers (Clarke et al., 2003). From
1990 to 2000 breast cancer mortality in the United States declined about 24% due to the
increased use of both mammographic screening and adjuvant therapy including
chemotherapy and antiestrogens (Ariazi et al., 2006).

Some dietary components can modify the ability of TAM to inhibit the growth of ER+
and perhaps also ER- breast cancer cells. Dietary components could either potentiate or
inhibit TAM actions. Ju et al. (2002) and Depypere et al. (2000) showed that genistein,
which found in soybeans and other plants, or tangeretin, which present in citrus fruits,
prevent TAM from inhibiting growth of malignant breast cells. In contrast, a few studies
have examined the positive effect of nutrition on TAM ability to inhibit the growth of
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breast cancer cells (Clarke et al., 2003). For example, the administration of Holoptelea
integrifolia plant compared with TAM gave a significant reduction of the tumor in six
female Sprague-Dawley rats after 120 days of treatments (Soujanya et al., 2011).

•

Nigella Sativa and Thymoquinone (TQ)

Alternative medicine in Saudi Arabia is very popular. For Islamic culture there are
many things that are described by god or by his prophets. Nigella Sativa is one of the
most popular seeds mentioned by Prophet Mohammad. He said that these black seeds are
a cure of everything except death. Some scientists have tested the effect of these seeds on
several organs and diseases because of this historical and religious background.

N. sativa is an annual capsulated plant used as a spice. It is a dicotyledon of the
Ranunculaceae family. It is usually grown in Europe, Middle East, and Western Asia
(Kanter et al., 2003). It is frequently used in folk medicine in the Middle East and Asia
for the promotion of good health and treatment of many ailments including fever,
common cold, headache, asthma, rheumatic diseases, various microbial infections, and to
expel worms (Salama, 2010). N. sativa contains 0.40–1.50% of volatile oil (essential oil
contains the volatile aroma component). The volatile oil has been shown to contain 18.4–
24% thymoquinone and 46% other monoterpenes such as p-cymene, and a-pinene (ElTahir et al., 1993), and to have insecticide, bronchodilator, immunomodulative (El-Kadi
and Kandil, 1987), antibacterial (Hanafy and Hatem, 1991), hypotensive (Zaoui et al.,
2000), choleretic, antitumoral (Salomi et al., 1992), antifungal, antihelmentic and
antiasthmatic (El-Tahir et al., 1993; Kanter et al., 2003) properties.
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The fixed oil (nonvolatile oil) of N. sativa is rich in unsaturated fatty acids while the
essential oil contains thymoquinone and carvacrol, which are antioxidants. Its seed
contains proteins, alkaloids (nigellicines and nigelledine), and saponins (α-hederin) in
substantial amounts. A review by Butt and Sultan (2010) described the effects of these
seeds on the improvement of oxidative stress through free radical scavenging activity, the
creation of apoptosis of cancerous cells, a decrease of blood glucose, and a protection of
complications from diabetes. N. sativa regulates hematological and serological
parameters and can be effective in dyslipidemia and respiratory disorders (Salama, 2010).
Most important to my study, thymoquinone is the component which had been shown to
treating breast cancer (Woo et al., 2011)

•

Reactive oxygen species and free radicals

Reactive oxygen species (ROS) are products of a normal cellular metabolism and play
roles in stimulation of signaling pathways in plant and animal cells in response to
changes of intra- and extracellular environmental conditions (Reuter et al., 2010). Some
ROS also contribute to pathophysiological conditions including mutagenesis and
carcinogenesis.

Our bodies constantly use oxygen for aerobic synthesis of ATP. As a consequence of
oxidative phosphorylation, highly reactive molecules, called free radicals, escape from
mitochondria (Worden, 2011). Unmanaged oxidation results in free radicals such as ROS
and reactive nitrogen species (NOS) that cause oxidative stress (Opara, 2004; Vina et al.,
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2006). Free radicals contribute importantly to tumor production by direct chemical
reaction or alteration of cellular metabolic processes (Soujanya et al., 2011).
These free radicals have been implicated in mediating various pathological processes
such as cancer, inflammatory diseases, diabetes, and atherosclerosis (Vina et al., 2006;
Wilson and Demmig-Adams, 2007).

In addition, ROS cause inflammation and carcinogenesis either directly by oxidation,
nitration, or halogenation of nuclear DNA, RNA, or lipids, or indirectly by the signaling
pathways activated by ROS. An example of ROS is the superoxide anion (O2-).
Manganese-superoxide dismutase (Mn-SOD) is the main endogenous enzyme for
protection against O2- by converting it into H2O2 and water (Karihtala and Soini, 2007).
H2O2 is another example of ROS, and may be formed either by dismutation from
superoxide anion or spontaneously in peroxisomes from molecular oxygen (Mates and
Sanchez-Jimenez, 2000; Valko et al., 2004). H2O2 plays an important role in generating
cancer because it is capable of diffusing out of the mitochondria and across cell
membranes to create oxidative damage within and outside the cell (Mates and SanchezJimenez, 2000; Ray G, Husain, 2002). H2O2 stress led to time-dependent increases in
intracellular oxidants, mitochondrial membrane polarization, cytochrome c release,
lysosomal rupture, and cell apoptosis (Yin et al., 2005). The hydroxyl radical (·OH)
usually resolves the damaging effect by ROS in the cell. It has a very unstable electron
structure and it’s unable to diffuse more than one or two molecular diameters before it
reacts with any cellular component (Reuter et al., 2010).
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•

Antioxidant and anticancer effects of Nigella Sativa and Thymoquinone

Free radicals are normally kept in check by the action of free radical scavengers that
occur naturally in the body. These scavengers neutralize the free radicals. Certain
enzymes serve this vital function, such as superoxide dismutase (SOD), catalase (CAT),
and glutathione peroxidase (GPx). These antioxidants also may protect against the
toxicity of ROS by the prevention of their formation (Soujanya et al., 2011). The
administration of antioxidant vitamins and trace elements is important for protecting the
body from oxidative stress and free radicals.

N. sativa seeds and extracts have been reported to be important in the treatment of
several diseases. They inhibit lipid peroxidation and prevent the formation of carbon
tetrachloride (CCI-4, which induces reactive free radicals which initiate cell damage) in
rats (Al-Ghamdi., 2003). Kanter et al. (2008) mentioned that N. sativa oil improves the
antioxidant defense mechanism in CCI-4 treated rats. In another study N. sativa provided
a protective effect against oxidative damage in isolated rat hepatocytes (Daba and AbdelRahmen, 1998).

Evidence supports an effect of N. sativa on immunity and inflammation. Nitric oxide
(NO) is an important factor in physiological processes and in disease states characterized
by inflammation. N. sativa extract caused a decreased NO production by murine
macrophages that also validated the traditional use of the N. sativa seeds for the treatment
of rheumatism (Mahmood et al., 2003). El-Kadi and Kandil (1986) studied the effect of
N. sativa on immunity after administering 1 g of these seeds twice a day to human
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subjects. Their results suggested that N. sativa improved immune functions by enhancing
helper T-cell (T4) to suppressor T-cell (T8) ratio and improving natural killer cell
activity.

An important effect of N. sativa is its anticancer effect. Its components are effective in
reducing cancer cell growth by the induction of apoptosis by tumor necrosis factor alpha
(TNF-α) (Butt and Sultan, 2010) .The administration of N. sativa, melatonin and retinoic
acid reduced the carcinogenic effects of 7, 12 di-methylbenz(a)anthracene (DMBA), a
drug used to induce mammary cancer experimentally. The frequency of mammary cancer
was high in the DMBA group (60%), followed by the treated groups which got the drugs
after administering DMBA (56%) and finally the prophylactic groups which got the drugs
before administering DMBA (33%) suggesting a protective role of N. sativa against
mammary cancer (El-Aziz et al., 2005).

Moreover, thymoquinone (TQ) has been reported to be effective in treating cancer.
Woo et al. (2011) investigated the effect of TQ on breast cancer cells in vitro. Three
different breast cancer cell lines (MCF-7, MDA-MB-231 and BT-474), each with distinct
characteristics, were used. MCF-7 and BT-474 are estrogen receptor (ER)-positive, and
MDA-MB-231 is ER-negative (Lacroix et al., 2004). The anti-proliferative effect of TQ
was determined by the 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium
bromide (MTT) assay. MTT solution was added to cancer cells after treatment with TQ
and left for 4 h. Cells were measured for their ability to reduce the yellow dye, MTT, to a
purple. The effect of TQ on the cell cycle was determined using flow cytometry analysis.
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The migration of cells was investigated using a ‘wound-healing’ assay. The protein
expression was investigated using immunoblotting. They found that TQ suppressed the
growth of all three breast cancer cell lines in a dose- and time-dependent manner. TQ
induced apoptosis in MCF-7 cells through the activation of caspases and increased
Bax/Bcl-2 ratio. The increase in total Bax/Bcl-2 ratio suggested that this might be one of
the mechanisms of TQ-induced apoptosis in MCF-7 cells. The migration of the cancer
cells was reduced with TQ-enriched medium, in a dose dependent manner. They also
combined TQ with doxorubicin and 5-fluorouracil (anticancer drugs) and found an
increased cytotoxicity indicating apoptotic induction.

Another study by Effenberger-Neidnicht and Schobert (2011) investigated the
anticancer affect of TQ and doxorubicin in human cancer cells. Doxorubicin (drug used
for cancer), TQ, and mixtures of both were tested for cytotoxicity on human cells of HL60 leukemia, 518A2 melanoma, HT-29 colon, KB-V1 cervix and MCF-7 breast
carcinomas. Apoptosis induction was analyzed by DNA fragmentation, activity studies of
the caspases-3, -8 and -9, determination of changes in the mitochondrial membrane
potential and in the ratio of the mRNA expressions of pro- and anti-apoptotic proteins
bax and bcl-2. The generation of ROS was assessed by the nitro blue tetrazolium (NBT)
assay. Their results showed that TQ improved the anticancer properties of doxorubicin in
a cell line-specific manner. They found a significant increase of the growth inhibition by
doxorubicin in combination with TQ. TQ was found to be a booster for the anti-cancer
effect of doxorubicin in certain cancer cell lines. Effenberger-Neidnicht and Schobert
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suggested that distinct improvements in efficacy, selectivity, and even breaches of multidrug resistance were observed for equimolar mixtures of doxorubicin and TQ.

•

Oxidative DNA Damage and 8-OHdG

Antioxidant defense systems cannot provide complete protection from noxious effects
of ROS. These effects include oxidative DNA damage, which animal and in vitro
experiments have suggested are important in carcinogenesis (Loft and Poulsen, 1996).
More than 100 modifications of DNA from ROS have been described including different
modifications of purines, pyrimidines, single-strand breaks and double-strand break
(Poulsen et al., 1998).

The ·OH-derived DNA damage includes the generation of 8-hydroxyguanosine (8OHG), the hydrolysis product of which is 8-hydroxydeoxyguanosine (8-OHdG). 8-OHdG
is the most commonly assayed fingerprint of free radical attack towards DNA (Marnett,
2002; Wiseman and Halliwell, 1996).

8-OHdG is involved in tumor progression. 8-OHdG has been reported to be enhanced
8- to 17-fold in breast primary tumors compared with normal breast tissue (Malins and
Haimanot 1991; Musarrat et al., 1996; Reuter et al., 2010). An elevated level of urinary
8-OHdG has been detected in patients with various cancers (Wu et al., 2004).
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•

Oxidative DNA Damage and Tamoxifen

A study by Bhimani et al. (1993) reported that TAM (2.5-20 µM per cell) decreased
the 12-O-Tetradecanoylphorbol-13-acetate (TPA)-mediated oxidative stress effect on 5hydroxymethyl-2'-deoxyuridine (HMdU) and 8-OHdG formation 2-29 times in HeLa
(cervical cancer) cells. Maximum inhibition occurred at 20 µm TAM, which caused an
approximately 95% reduction in HMdU and 8-OHdG. They were investigating TPA
effect on oxidative stress in HeLa cells and the inhibition effect by TAM using 3Hpostlabeling of 8-OHdG. TPA treatment (10 fmol/cell) caused about 5-10-fold increase
in 8-OHdG and HMdU (10 nmol TPA/ml), while TAM caused reduction of both. Their
finding suggested that TAM is a chemopreventive agent, which at very low doses
decreases the tumor promoter-mediated oxidative processes.

However, their study did not test the effect of TAM on DNA damage of normal cells.
TAM treatment can lead to DNA damage in normal cells, but the mechanism of this
process is not fully understood. Wozniak et al. (2007) compared the DNA-damaging
potential of TAM in MCF-7 breast cancer cells and normal human peripheral blood
lymphocytes by using the comet assay. For evaluating the involvement of free radicals in
the genotoxicity of TAM they pretreated the cells with nitrone spin traps: DMPO and
POBN. Vitamin C, amifostine and genistein in breast cells were used to evaluate the
contribution of free radicals. TAM damaged DNA in normal and cancer cells, causing
DNA strand breaks. TAM at 5 and 10 µM induced DNA double strand breaks in normal
lymphocytes and at 10 µM in MCF-7 cells. In both types of cells TAM induced oxidized
purines and pyrimidines. Their results suggested that TAM can be genotoxic for normal
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and cancer cells by free radical generation. TAM also had a higher genotoxic potential
for normal cells, which could be the result of incomplete repair of DNA double strand
breaks. They mentioned that free radical scavengers can modulate TAM-induced DNA
damage interfering with its antitumor activity in cancer cells.

•

Oxidative DNA Damage and Thymoquinone

The concerns about cancer drugs and DNA damage made scientists dedicate their
efforts to finding natural treatments such as N. sativa. Koka et al. (2010) investigated the
mechanism of action of TQ in androgen receptor (AR)-independent (C4-2B) and AR
naive (PC-3) prostate cancer cells. They exposed cells for 24–48 h to TQ (25–150
mmol/L) and observed inhibition of the growth of both types of cancer cells. TQ also upregulated the expression of growth arrest and DNA damage inducible gene (GADD45a)
and apoptosis-inducing factor-1.

Another study by Rastogi et al. (2010) investigated the protective effect of N. sativa
against radiation-induced oxidative damage. Single cell gel electrophoresis assay and
micronuclei formations were used to determine DNA damage. Biochemical methods
were used to determine the alterations in lipid peroxidation and antioxidant enzymes.
Using mouse splenic lymphocytes treated with an ethanolic extract of N. sativa 1 h prior
to irradiation caused a significant prevention of the formation of lipid peroxides and
intracellular ROS. Moreover, they found prevention of DNA damage which was
measured by the bone marrow micronuclei assay.
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As mentioned previously, Woo et al. (2011) investigated the effect of thymoquinone
(TQ) on breast cancer cells. They found that TQ suppressed the growth of all three breast
cancer cell lines in a dose- and time-dependent manner. TQ induced apoptosis in MCF-7
cells. It is also reduced the migration of the cancer cells. Moreover, when TQ was
combined with doxorubicin and 5-fluorouracil (anticancer drugs) there was an increase in
cytotoxicity to the cancer cells. They also reported for the first time that TQ was able to
increase peroxisome proliferator-activated receptor gamma (PPAR-γ) activity which
down-regulates the expression of the genes for Bcl-2, Bcl-xL. PPAR-γ activation leads to
growth inhibition, apoptosis and differentiation of tumor cells. More importantly, the
increase in PPAR-γ activity was prevented in the presence of PPAR-γ specific inhibitor
and PPAR-γ dominant negative plasmid, suggesting that TQ may act as a ligand of
PPAR-γ.

A study by Gurung et al. (2010) was performed to investigate the cytotoxic effect of
TQ in brain tumor and normal cells. They demonstrated that glioblastoma (brain cancer)
cells were more sensitive to TQ induced antiproliferative effects than were normal cells.
TQ caused DNA damage, cell cycle arrest and apoptosis in the glioblastoma cells. The
single-cell gel electrophoresis (comet assay) under alkaline conditions was used to
determine the DNA damage.
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•

Glutathione

Glutathione (GSH) is a tripeptide and the major endogenous antioxidant produced by
animal and plant cells. It helps to protect cells from ROS, free radicals, and peroxides.
GSH has a role in regulating cell apoptosis. GSH is emerging as a regulator of the
expression of proteins (or molecules) involved in apoptosis or inflammation. In the
cytoplasm, overproduction of ROS and the resulting decrease in GSH activates various
transcription factors (like p38 protein) which migrate into the nucleus to activate gene
transcription. Therefore, glutathione plays a primary role in maintaining a normal redox
status and in regulating transcription of genes (Pincemail et al., 2001).

GSH is present inside cells mainly in the reduced form (90–95% of the total
glutathione). Oxidation of glutathione leads to the formation of glutathione disulfide
(GSSG). The glutathione transferases (GSTs) are one of the most important families of
detoxifying enzymes in nature. The classic activity of the GSTs is conjugation of
compounds with electrophilic centers to GSH (Oakley, 2011)

In terms of cancer prevention, GSH can inhibit cancer development through phase II
metabolism and subsequent export of toxic chemicals from the cell. (Konishi et al., 1997;
Alliangana, 1996; Reuter et al., 2010). The pi-class glutathione S-transferase (GSTP1)
activity, for example, protects cells from carcinogens in the human prostate. Kanwal et al.
(2012) studied the protective effect against oxidative DNA damage and stress by GSTP1
in human prostate. They found high levels of 8-OHdG in adenocarcinomas, compared to
benign counterparts, which positively correlated (r = 0.2) with loss of GSTP1 activity.
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Suppressing GSTP1 using an siRNA approach in normal prostate cells caused elevated
intracellular production of ROS. In contrast, induction of GSTP1 activity lowered
endogenous ROS levels in cells and significantly reduced 8-OHdG levels compared to
the controls. This study suggested a negative correlation between glutathione Stransferase and 8-OHdG levels.

TAM was observed to reduce GSH production. A study using TAM by Bruning et al.
(2010) observed a significant reduction of the GSH level by 7% for MCF7 cells treated
with 6 µg /ml TAM. In contrast with using a different drug (nelfinavir) they observed
more reduction in the intracellular GSH than TAM in concentration of 6 µg /ml. The
combination of nelfinavir and TAM did not reduce the GSH levels in breast cancer cells
in a significant manner like nelfinavir by itself. However, the intracellular GSH levels
might vary not only because of external drug applications, but also due to differences in
cell growth, nutrient concentrations, and the redox state within the cells or of the
surrounding medium. These errors could be avoided by using animal models and
measuring the overall levels from the body. Moreover, oxidative DNA damage was not
related to GSH. More investigation is needed.

In contrast, TQ enhances GSH formation. Quinones, naturally found in the human
body and environment, are highly reactive molecules that can be metabolized to free
radicals and cause oxidative damage. However, quinone reductase (QR) has been found
to protect against quinone toxicity (Cheng, 2006). TQ induces QR and GSH transferase
in mouse liver. Nagi and Almakki (2009) found a possible role in protection against
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chemical carcinogenesis and toxicity by TQ. Protection could be mediated by induction
of detoxifying enzymes, including quinone reductase and glutathione transferase. TQ was
administered to mice (1, 2 and 4 mg/kg/day) for five days to measure quinone reductase
and glutathione transferase in livers. TQ uptake increased the activities of quinone
reductase (147, 196 and 197% of control, respectively) and glutathione transferase (125,
152 and 154 % of control, respectively). This result makes TQ appear to be a promising
preventive agent against chemical carcinogenesis and toxicity.

A recent study by Harzallah et al. (2012) reported a significant increase in the
antioxidant enzymes catalase (CAT), superoxide dismutase (SOD), and glutathione
peroxidase (GPX) enzyme levels by 50.23 %, 12.55 %, and 352.9 %, compared to
controls in rats with colon cancer treated with TQ. They used 25 rats divided into 5 per
group and treated weekly. The five groups were: 1- saline, 2-TQ, 3-DMH procarcinogen,
4- pre-treatment (TQ + DMH) (10 weeks), and 5- post-treatment DMH cancer inducer
drug (10 weeks) + TQ (10 weeks) treated rats. DMH dose was 20mg/kg bw and TQ dose
was 5mg/kg bw.

•

Introduction summary

In summary, numerous in vitro and in vivo studies have provided evidence that TQ
could prevent carcinogenesis and inhibit tumorigenesis through different molecular
mechanisms. They determined the antioxidant enzyme activities by using assay kits for
catalase activity, superoxide dismutase activity and glutathione peroxidase activity (Woo
et al., 2012; Harzallah et al., 2012). On the other hand, TAM is reported to be effective
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in the prevention and protection against cancer, but it has a negative effect on GSH levels
and 8-OHdG. TAM was reported to damage DNA in normal and cancer cells (Wozniak
et al., 2007).

Some dietary components however can modify the activity of TAM. The concerns
about cancer drugs and DNA damage made scientists dedicate their efforts to find natural
treatments like N. sativa. TQ was reported to be effective as an anticancer treatment
(Woo et al., 2011). TQ was reported to prevent DNA damage. TQ also was able to
increase PPAR-γ activity which down-regulates the expression of some genes (Woo et
al., 2011). In addition, TQ was found to induce QR and GSH transferase activity (Rastogi
et al., 2010).

•

Mammary cancer induction in rats

Scientists have discovered many specific drugs that induce cancer in rats. Mammary
glands of several rat strains, mainly Sprague-Dawley, are susceptible to transformation
induced by chemical carcinogens, and the two most widely used active chemical inducers
of mammary carcinogenesis are 7,12 dimethylbenz (a)anthracene (DMBA) and Nmethylnitrosurea (Barros et al., 2004). DMBA produces rat mammary cancer and has
been widely used in cancer studies since it was first reported by Huggins et al. (1961)
(Motoyama et al., 2005). One dose of DMBA by oral gavage leads to up-regulation of the
cellular cytosolic receptor for DMBA, the aryl hydrocarbon receptor (AhR) (Trombino et
al., 2000). This activated AhR/ARNT complex then binds to specific DNA recognition
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sites upstream of AhR responsive genes and causes gene transcription which in the end
forms DNA adducts (Denison and Nagy, 2003).

Hypotheses
My first hypothesis was that TQ would decrease 8-OHdG in rats’ plasma more than
TAM. I also predicted that the combination of TAM and TQ would reduce 8-OHdG more
than TAM by itself. 8-OHdG is the most commonly assayed fingerprint of free radical
attack on DNA (Marnett, 2002; Wiseman and Halliwell, 1996). 8-OHdG is also involved
in tumor progression.

My second hypothesis was that that TQ would increase the production of GSH more
than TAM in Sprague-Dawley rats. I also predicted that the combination of TAM and TQ
would have the best result in enhancing GSH production. GSH plays an important role in
protecting cells from ROS and 8-OHdG, both of which are involved in cancer. It is now
well understood that ROS can damage DNA. GSH on the other hand can protect
against this type of damage (Kanwal et al., 2012).

Methods
•

Animals

Fifty female Sprague-Dawley rats were obtained from the EWU vivarium. Rats were
born August 8-15, 2012, were between 179-261 g body weights.
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The number of rats was 10 per group in five groups. This number was determined by a
power analysis (Quinn & Keough, 2002). Mishra et al. (2012) used six rats per group and
treated rats with TAM. The power of their experiment was 0.05 which is so low due to
the sample size. In contrast, Kanter et al. (2003) used 15 rats per group and treated them
with TQ. The power of their experiment was 1. Another study by Singh et al. (2011)
used at least 8-10 rats samples to find the effect of TAM on 8-OHdG. Their power was
0.97. These findings suggested that six rats are not enough and 15 are too many, while 10
would be sufficient.

The rats were housed in pairs in the EWU vivarium and allowed free access to water
and Teklad 8640 Standard Rodent Diet. The room temperature was 26 ± 1 ºC, humidity
was 25-30% and photoperiod was a 12-hour light/12-hour dark cycle. Body weight was
recorded weekly. Cages were cleaned weekly and changed every 4 weeks. I got approval
from the EWU Institutional Animal Care and Use Committee before I began rat
treatments.

•

Treatments

There were five different groups (n=10 per group):
1. Controls: received tap water only, daily for 10 wk.
2. DMBA group: received one dose of DMBA, and tap water daily for 10 wk.
3. TAM group: received one dose of DMBA, and TAM daily for 10 wk.
4. TQ group: received one dose of DMBA, and TQ daily for 10 wk.
5. TAM + TQ group: received one dose of DMBA, and TAM + TQ daily for 10 wk.

21

A first dose of DMBA was given by oral gavage to the following groups: DMBA,
TAM, TQ, TQ+TAM. After three weeks, the other drugs were administered by oral
gavage 7 days per week for 10 weeks. A second dose of DMBA was administered to the
same groups in the 4th week because of an insufficient first dose due to incorrect
measurements with the oral gavage needle.

For oral gavage I extended the rat’s head back using an index finger on top of the head
to raise the head so the esophagus was in a straight line. Next, I inserted the gavage
needle into the rat’s mouth. Once the gavage needle was properly placed with the end of
the gavage needle in the rat’s stomach, I slowly administered the dose. After
administration, I slowly removed the gavage needle from esophagus.

•

Drugs and drug administration

DMBA was purchased from Sigma Aldrich and was mixed with corn oil with a
shaker. Corn oil was purchased at a local grocery store. A DMBA dose of 20 mg /kg
(Motoyama et al., 2008) was administered. The total volume of DMBA needed for all of
the 40 rats was determined. For the average body weight of 250 g, the total volume of
DMBA was 200 mg. Therefore, I prepared a solution containing 200 mg of DMBA
mixed with 10 ml of corn oil. The dose in ml per rat was calculated as following: the rat
weight in g/ 1000. For example if the rat weight was 250 g the dose was 0.25 ml of the
solution.

22

Because DMBA induces cancer and contains a component that has been reported to be
probably carcinogenic for humans, I protected myself as follows:
1. DMBA was locked in safety box.
2. I covered all the surfaces such as walls, desks, the fume hood and door handles
with plastic.
3. I put on disposable lab coats, long double gloves, face shield and mask.
4. Rats were given DMBA under the fume hood to minimize contamination.
5. The insides of rats’ cages were covered with absorbent sheets so that vomiting
could be observed and contained.
6. Each rat was placed under the fume hood and given the dose and observed for 5
minutes in its cage.
7. After finishing all the rats I removed the absorbent sheets from their cages and
cleaned the outside surface of the cages with 70% alcohol.
8.

After that I put all of the sheets and covers with gavage needles, lab coats, gloves
and DMBA container into hazard disposal bags and cleaned the room with soap
and 70% alcohol.

9. After one week the rats’ bedding was sent to hazard disposal.
10. After two weeks the rats’ cages were cleaned and washed twice in EWU
Vivarium’s cage washer followed by two empty cycles of the cage washer to
minimize contamination of the cage washer.
11. I washed the rats with clean water and placed them under a heating lamp until
they dried.
12. Rats were then placed into their clean cages.
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TAM was purchased from Cayman Chemical. The TAM dose was 10 mg/kg /day
dissolved in water (Soujanya et al., 2011). The total volume of TAM needed for all 20
rats was determined. For the average body weight of 250 g the total volume of TAM was
50 mg. I prepared a solution containing 50 mg of TAM dissolved in 5 ml water daily. The
dose in ml per rat was calculated as following: the rat weight in g/ 1000.

TQ was purchased from Sigma Aldrich. The dose of TQ was 20 mg/kg/day dissolved
in corn oil (Nagi and Almakki, 2009). The total volume of TQ needed for all 20 rats was
determined. For the average body weight of 250 g the total volume of TQ was 100 mg. I
prepared a solution containing 100 mg of TQ mixed with 10 ml of corn oil daily. The
dose in ml per rat was calculated as following: the rat weight in g/ 1000.

The TAM+TQ group received the same doses of TAM and TQ. The solutions were
prepared as described previously. The dose was administered in the same oral gavage at
the same time. The maximum volume for 250 g rat was 0.25 ml of TAM solution and
0.25 of TQ solution.

•

Blood Samples

After 10 weeks of treatment blood was collected by cardiac puncture. Before cardiac
puncture, each rat was anesthetized with isoflurane, using Dr. Carlberg’s chamber
method. The rat was removed from the chamber when it was unconscious, and its nose
was placed in a cone containing isoflurane-soaked cotton. After cardiac puncture the rat
was placed in another chamber, with a higher level of isoflurane, for euthanasia.
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The following procedure was described by Beeton et al. (2007) and was modified
according to Dr. Carlberg’s method:

1. 5 ml of distilled water were added to one heparin tablet (Sigma Aldrich
H3393).
2. 21G X 1.5 inch needles with 3 cc syringes were coated with heparin to
prevent blood clotting during cardiac puncture.
3. Two chambers were prepared for isoflurane by adding layers of paper towels
in their bottoms.
4. The first chamber contained 6 ml of isoflurane, while the second one
contained 15 ml of isoflurane.
5. Nose cotton was prepared with 3 ml of isoflurane in case rats awakened.
6. A rat was anesthetized in the first chamber.
7. The rat was moved around inside the chamber to determine if it was
anesthetized.
8. The rat was placed on its back, facing away from me.
9. My left index finger was placed at the level of the lowest ribs, without
applying any pressure. The heart was located ~ 1 cm above this point, slightly
to the rat’s left side. After feeling the heart the needle was inserted below the
xiphoid and through the diaphragm. Blood was drawn by inserting the needle
into a ventricle. Approximately 3 ml of blood was drawn from each rat.
10. After cardiac puncture the rat was placed into the second chamber, with the
higher level of isoflurane, for euthanasia.
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11. Needles were placed in the sharps container and blood samples were moved to
the cold centrifuge at 4 °C.

Blood samples were centrifuged at 600 x g, 4 °C for 10 minutes to separate red blood
cells from the plasma. Red blood cells were used for the GSH assay, and plasma was
used for the 8-OHdG measurement. I separated the plasma from cells and divided the
plasma into three aliquots, one for the 8-OHdG test and the other two for Nadiah AlOtaibi’s studies. The red blood cells were saved in different aliquots for the GSH test. All
aliquots were labeled and frozen at -80 °C.

•

Oxidative DNA Damage ELISA Assay (8-OHdG Quantitation)

The oxidative DNA damage ELISA assay kit was obtained from Cell Biolabs, Ins. I
used the protocol from the product manual. In summary, this kit is an enzyme
immunoassay made for detection and quantitation of 8-OHdG in plasma, or other
samples. I used plasma to detect 8-OHdG quantity. The quantity of 8-OHdG in a plasma
sample is found by comparing its absorbance with a 8-OHdG standard curve.

Before starting the assay I did a practice test and several evaluations of extra plasma
from three rats to determine the best dilution for the standard curve. I figured out that a
20 fold dilution was the best to use. In addition, I needed to separate the rats into two
plates, each containing half of the rats because one plate was not enough for all of the
samples in duplicates. Therefore, I did the test twice.
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The 8-OHdG assay included the following steps:
1. Plasma was diluted 20 fold by adding 10 µl of thawed plasma to 190 µl Assay
Diluent.
2. For coating the plate: 8-OHdG Conjugate was diluted 1 mg/mL to 1 µg/mL of 1X
PBS. Then 100 µL of the 1 µg/mL 8-OHdG Conjugate was added to each well
and incubated overnight at 4 °C.
3. On the following day a spectrophotometer was prepared using 450 nm.
4. For washing the plate: Wash Buffer (100 ml) was Diluted by adding 900 ml of
distilled water.
5. The 8-OHdG coating solution was removed and washed once with distilled water
and the plate was blotted on paper towels to remove excess fluid.
6. 200 µL of Assay Diluent was added to each well and kept for 1 hr at room
temperature.
7. Then the plate was transferred to 4ºC or Assay Diluent was removed immediately
before the next step.
8. A 8-OHdG standard curve was prepared using the product manual (Table 1).
9. Rats’ plasma and the standard curve solutions could not all fit into one 96 well
plate. Therefore, they were divided into two separate plates, each containing five
rats’ plasma from each group and their standard curve.
10. 50 µl of diluted plasma or 8-OHdG standard were added into the wells in
duplicates and incubated at room temperature for 10 minutes on an orbital shaker.
11. Anti-8-OHdG Antibody was diluted 1:500 with Assay Diluent.
12. Rats’ plasma was removed from the freezer 30 minutes before the assay started.
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13. 50 µL of the diluted anti-8-OHdG antibody was added to each well and incubated
at room temperature for 1 hour on an orbital shaker.
14. Secondary Antibody was diluted 1:1000 with Assay Diluent.
15. Micro-well strips were washed 3 times with 250 µl 1X Wash Buffer per well with
aspiration.
16. 100 µL of the diluted Secondary Antibody-Enzyme Conjugate was added to all
wells and incubated at room temperature for 1 hour on an orbital shaker.
17. The Substrate Solution was removed from the refrigerator and warmed to room
temperature.
18. Micro-well strips were washed as in step 13.
19. 100 µL of Substrate Solution was added to each well and incubated at room
temperature on an orbital shaker.
20. The plate was watched carefully for color changing for 2-10 min. It was stopped
when the standard curve wells showed different color gradations.
21. The enzyme reaction was stopped by adding 100 µl of Stop Solution into each
well.
22. Rat’s plasma absorbance was read immediately using the spectrophotometer at
450 nm.
23. The 8-OHdG content in unknown samples was determined by comparison with
the 8-OHdG standard curve.
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Standard Tubes

8-OHdG Standard (µ
µl)

Assay Diluent (µ
µl)

8-OHdG (ng/ml)

1

10

990

20

2

500 of additional tube that has

500

5

500 of tube #1+ Assay Diluent
3

500 of tube #2

500

2.5

4

500 of tube #3

500

1.25

5

500 of tube #4

500

0.625

6

500 of tube #5

500

0.313

7

500 of tube #6

500

0.156

8

500 of tube #7

500

0.078

9

500 of tube #8

500

0

Figure 2: 8-OHdG standard curve

•

Glutathione assay

A GSH assay kit was purchased from Sigma Aldrich. The GSH kit uses a kinetic
assay in which catalytic amounts (nmoles) of GSH cause a continuous reduction of 5,5dithiobis(2-nitrobenzoic acid) (DTNB) to TNB and the GSSG formed is recycled by
glutathione reductase and NADPH. The reaction rate is proportional to the concentration
of glutathione up to 2 mM. The yellow product, 5-thio- 2-nitrobenzoic acid (TNB) is
measured spectrophotometrically at 412 nm. The assay uses a standard curve of reduced
glutathione to determine the amount of glutathione in the biological sample (Sigma
Aldrich product manual).
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I prepared the rat’s red blood cells immediately after cardiac puncture as following:
1. First, I prepared the working solutions:
o 5-sulfosalicylic acid (5-SSA) 2.5 g was dissolved in 50 ml of water.
o PBS was prepared by adding 200 ml of water to a PBS tablet.
2. PSB was added three times the volume of red blood cells in the tube and
centrifuged at 600 x g at 4°C for 10 minutes.
3. The supernatant was removed and PSB was added again and centrifuged at
600 x g at 4 ºC for 10 minutes.
4. The supernatant was removed again and 200 µl of the red cells (bottom) was
added to 200 µl of 5-SSA in centrifuge tubes.
5. All tubes were vortexed and kept for10 min at 4 ºC.
6. After that the tubes were centrifuged at 10,000 x g in the cold room for 10
minutes.
7. 20 µl of the top solution was diluted 10 fold with Assay Buffer.
8. Red blood cells samples were frozen at -80 °C until assayed.

Before starting the assay I did a practice test and several evaluations of red blood cells
from six extra rats to determine the best dilution for the standard curve and to determine
the best volume of the sample needed to start the reaction. I found that a 10 fold dilution
and 6 µl of the sample after dilutions is the best to use in the assay. I also found out that
the reaction and the color change very quickly. Therefore, I needed to separate the rats
into five plates, each containing one or two rats from each group at a time to avoid
pipetting delay.
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After few days from collecting blood, GSH assay stock solutions were prepared as
follows:
1. Assay Buffer was prepared by adding 4.8 ml of it to 19.2 ml distilled
water.
2. Enzyme Solution was prepared by adding 3.8 µl of Glutathione Reductase
to 246.2 µl Assay Buffer.
3. Working Mixture was prepared by the addition of 8 ml of Assay Buffer,
228 µl and 228 µl of DTNB Stock Solution with mixing thoroughly.
4. NADPH Solution was prepared by adding 10 µl NADPH stock solution to
2.5 ml Assay Buffer.

GSH assay steps:
1. Spectrophotometer was set to 412 nm as kinetic assay, which uses the slope
of the sample, at 10 minutes with shaking every 20 seconds.
2. Rats’ red blood cells were divided into five separate plates and each group
was removed from the freezer 30 minutes before the assay started.
3. To avoid pipetting errors blood cells were transferred to the wells as
follows: 24 µl of blood cells were added to 16 µl of 5-SSA and then I took
10 µl of the working mixture to wells in duplicates.
4. Glutathione Standard Curve Solutions were prepared in duplicate
(Table 2).
5. Two blank wells were created by adding only 10 µl of 5-SSA to each well.
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6. 150 µl of the Working Mixture was added to all wells with a repeating
pipette and incubated for 5 min at room temperature.
7.

50 µl of NADPH Solution was added to all wells with a repeating pipette
and mixed in an orbital shaker for 1 min.

8. The Spectrophotometer was used to measure the absorbance in rat’s red
blood cells.

Standard Tubes

GSH Concentration

GSH Solution

5% SSA

nmoles GSH in

(µ
µl)

(µ
µl)

(ng/ml)

a 10 µl sample

1

50

50

None

0.5

2

25

25 from tube #1

25

0.25

3

12.5

25 from tube #2

25

0.125

4

6.25

25 from tube #3

25

0.0625

5

3.125

25 from tube #4

25

0.0312

6

1.625

25 from tube #5

25

0.015

7

0.812

25 from tube #6

25

0.007

8

0.406

25 from tube #7

25

0.003

9

0.203

25 from tube #8

25

0.001

10

0.10

25 from tube #9

25

0

Figure 3: GSH standard curve preparation
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Total GSH was calculating from the equation:

D A412/min (sample) = slope generated by sample (after subtracting the values
generated by the blank reaction).
D A412/min (1 nmole) = slope calculated from standard curve for 1 nmole of GSH
dil = dilution factor was 10 fold
vol = volume of sample in the reaction was 6 µl which is 0.006 ml.
I used the values of the Glutathione Standard Solutions equivalent to 1 nmole of reduced
glutathione per well.

•

Rats’ body weights

Rats’ body weights were measured weekly for 12 weeks. The weight gain was
calculated by subtracting the starting weight from the last weight.

•

Statistical analysis

For 8-OHdG, a mean of duplicate wells was used for each rat. Data were collected
from two different immunoassay plates, each with its own standard curve, with half the
rats from each group on each plate. Therefore, I did a two-sample t-test on the
transformed data from the two plates to see if the plates differed significantly. I found
that there was no significant difference between the two plates. 8-OHdG data did meet
the criteria for parametric tests because the data were normally distributed. A one way
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ANOVA test was used, followed by Pairwise Multiple Comparison Procedures (Fisher
LSD Method) with α set at 0.05. This test was applied using Sigma Plot software.

For GSH a mean of triplicate wells was calculated for each animal. The data were
collected from five different plates because the reaction and the color changed very
quickly. Because there always are slight variations among standard curves, data could not
be combined from the five plates for a parametric test. Therefore, the Kruskal-Wallis test
was used with α set at 0.05. This test was applied using InStat software.

Body weight data were normally distributed so one way ANOVA was used, followed
by Pairwise Multiple Comparison procedures (Fisher LSD Method) with α set at 0.05.
This test was applied using Sigma Plot software.

Results
Tumors were found in only two DMBA treated rats. Both tumors were near the axilla
(Figure 4). However, there was a coloration observed in the mammary glands in four of
the other DMBA treated rats. A dark red to black color was observed in the mammary
gland position (Figure 5). Therefore, six of the 10 DMBA treated rats had changes in the
mammary glands, but none of the rats in the other groups did.

Three TQ treated rats died because of drug administration errors. TQ was mixed with
oil and that caused the gavage needle to become slippery. Unfortunately, after
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administering the dose three TQ treated rats were having difficulty breathing and died
eventually.

Figure 4: Mammary tumor in one of the DMBA treated rats. The tumor was found
near the axilla after dissecting the rat.

Figure 5: Mammary gland coloration in one of the DMBA treated rats. The
coloration was found after dissecting the rat. The black arrow shows the coloration
position.

35

One way ANOVA test showed that plasma concentration of 8-OHdG differed
significantly among groups (P= 0.002). Pairwise Multiple Comparison Procedures
(Fisher LSD Method) showed that 8-OHdG was significantly higher in the TAM group
compared with the TQ (P <0.001), the control (P= 0.008) and the DMBA (P=0.041)
groups. TQ significantly decreased 8-OHdG by itself compared with DMBA (P= 0.039)
and TAM, but did not significantly reduce the effect of TAM in the TAM+TQ group. The
TAM+TQ group was significantly higher than the TQ group (P= 0.002) (Figure 6).
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1.4
1.2

8-OHdG ng/ml

1
0.8
0.6
0.4
0.2
0
Control

DMBA

TAM

TQ

TAM+TQ

Figure 6: Values are means ± S.D. for 8-OHdG levels in Control, DMBA, Tamoxifen
(TAM), Thymoquinone (TQ), and TAM+TQ groups. 8-OHdG levels depend on
plasma absorbance at 450 nm using a spectrophotometer. 8-OHdG data showed a
significant difference among the groups (P= 0.002) using the One Way ANOVA test.
8-OHdG was significantly higher in the TAM group compared with the TQ (P
<0.001), the control (P= 0.008) and the DMBA (P=0.041) groups. TQ significantly
decreased 8-OHdG by itself compared with DMBA (P= 0.039) and TAM. The
TAM+TQ group was significantly higher than the TQ group (P= 0.002) using
Pairwise Multiple Comparison Procedures.

In contrast, the Kruskal-Wallis test for GSH in red blood cells showed that GSH
levels did not differ among the groups (P=0.7). Therefore TQ did not change GSH levels
by itself or combined with TAM (Figure 7).
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/ml
Figure
ure 7: Total glutathione (nmole /ml) in Control, DMBA, Tamoxifen (TAM),
Thymoquinone (TQ), and TAM+TQ groups. There was no significant difference
among the groups (P= 0.7) using Kruskal-Wallis test. (

) shape represents two

times repeated value.

one-way
way ANOVA for gain in body weight over 12 weeks
On the other hand, the one
showed a significant difference among the groups (P<0.001). The results from Pairwise
Multiple Comparison procedures showed that the TAM group had a lower weight gain
compared with the TQ (P=0.012), the control (P
(P<0.001) and the DMBA (P<
(P 0.001)
treated groups. Also the TAM+ TQ group showed significantly less weight gain
compared with the control (P< 0.001), the TQ (P= 0.002) and the DMBA (P<
(P 0.001)
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treated groups. In contrast, the TQ group did not differ from the controls and the DMBA
groups (Figure 8).

40
35

Mean weight gain (g)

30
25
20
15
10
5
0
Control

DMBA

TAM

TQ

TAM+TQ
TAM

Figure 8: Values are means ± S.D. for weight gain over 12 weeks among the groups:
Control, DMBA, Tamoxifen ((TAM),
TAM), Thymoquinone (TQ), and TAM+TQ.
TAM+TQ ANOVA
showed a significant difference among the groups (P <0.001). The TAM group
showed significantly less weight gain compared with the TQ (P=0.012),
(P=0.012) the control
(P<0.001) and the DMBA (P< 0.001) treated groups
groups. Also the TAM+ TQ group
showed significantlyy less weight gain compared with the control (P< 0.001), the TQ
(P= 0.002) and the DMBA (P< 0.001) treated groups.
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Discussion
Tumors were found in only two DMBA treated rats but there was a dark coloration
observed in the mammary glands of another four rats in this group. Rao & Das (1985)
reported that when 20 mg of DMBA was given to rats that were maintained on normal
diet for 32 weeks, approximately 70% of the animals developed mammary tumors. They
also mentioned that the addition of aminoglutethimide to animals’ diets reduced the
number of tumors. In my study, if we counted the tumors and the coloration in the
mammary glands together, 60% of the DMBA treated rats developed mammary gland
changes in only 12 weeks. However, there were no tumors or colorations in the rest of
the groups. Thus, there is a possibility that the TAM, TQ and TAM+TQ treated groups
had no tumors because of the protective role of these treatments.

TQ has been reported to be effective in treating cancer. Woo et al. (2011) investigated
the effect of TQ on breast cancer cells. They found that TQ suppressed the growth of all
breast cancer cell lines in a dose- and time-dependent manner. In addition, the
combination of TQ and Doxorubicin (drug used for cancer) was studied by EffenbergerNeidnicht and Schobert (2011) and showed that TQ improved the anticancer properties of
doxorubicin in a cell line-specific manner. Moreover, TAM is the most widely prescribed
drug for the prevention and the treatment of breast cancer (Curtis, 2001). My study
provides more evidence that both TQ and TAM may be effective in preventing the
development of cancer.
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In my study 8-OHdG was significantly higher in rats’ plasma in the TAM group
compared with the TQ (P <0.001), the control (P= 0.008) and the DMBA (P=0.041)
groups. The National Institute for Environmental Health Sciences listed substances that
are known to cause cancer and Tamoxifen was one of them (New York Times, 2000). It
was known to cause uterine cancer (Grady, 2013). In my study TAM significantly
increased 8-OHdG compared with TQ, which may be a reason that TAM induces
different types of cancer. TQ could be a better anticancer drug than TAM because it
decreases 8-OHdG. My result suggested that TQ could be a promising natural, healthy
nutrient that protects against 8-OHdG which is the most commonly assayed fingerprint of
free radical attack towards DNA. 8-OHdG is also known to be involved in tumor
progression (Marnett, 2002; Wiseman and Halliwell, 1996).

Notably, TAM has been reported to increase DNA damage not only in cancer cells but
also in normal cells. Wozniak et al. (2007) compared the DNA-damaging potential of
TAM in MCF-7 breast cancer cells and normal human peripheral blood lymphocytes.
They found that TAM damaged DNA in normal and cancer cells, causing DNA strand
breaks. In my study TAM increased 8-OHdG compared with the control, DMBA and TQ
groups.

TQ has been reported to protect normal cells from DNA damage. A study by Rastogi
et al. (2010) investigated the protective effect of N. sativa against radiation-induced
oxidative damage. They found a significant prevention of the formation of lipidperoxides and intracellular ROS. Moreover, the prevention of DNA damage was
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observed. In my study I am suggesting that the active component of N. sativa is TQ,
which reduced 8-OHdG compared with TAM and DMBA groups.

In another study, TQ by itself showed a selective effect toward cancer cells. Gurung et
al. (2010) investigated the cytotoxic effect of TQ in brain tumor and normal cells. TQ
caused DNA damage, cell cycle arrest and apoptosis in the glioblastoma (brain cancer
cells) only, but not in normal cells. Thus, TQ did not cause any damage to normal cells.
Another study by Woo et al. (2011) reported for the first time that TQ was able to
increase PPAR-γ activity which down-regulates the expression of the genes for Bcl-2,
Bcl-xL and decreases the survival of breast cancer cells. Therefore, TQ appears to have a
protective role toward the whole body by causing DNA damage in cancer cells and
protecting normal cells, unlike TAM which causes DNA damage in both normal and
cancer cells. In my study there was no difference in 8-OHdG levels between the TQ and
the controls but TQ decreased 8-OHdG compared with TAM and DMBA groups.

Conversely, total glutathione (GSH) in red blood cells did not differ among the groups
(P=0.7). GSH helps to protect cells from ROS, free radicals and peroxides (Pincemail et
al., 2001). In fact, TAM has been observed to reduce GSH production. A study by
Bruning et al. (2010) observed a significant reduction of the GSH level by 7% for MCF7
(cancer cells) treated with TAM. However, in my study total GSH in red blood cells did
not differ from other groups. This is could be because Bruning et al. used TAM on cancer
cells and they studied GSH at a molecular level rather than as total GSH in red blood
cells. On the other hand, glutathione peroxidase (GPX) was reported to be significantly
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increased compared to controls in rats with colon cancer treated with TQ (Harzallah et
al., 2012).

The main role of GPX is to protect an organism from oxidative damage by catalyzing
the reaction:
2GSH + H2O2 → GSSG + 2H2O
in which the reduced GSH forms glutathione disulfide (GSSG). GSH+ GSSG constitute
the total GSH in the body. In the Harzallah et al. (2012) study, GPX level increased
compared to controls in rats with colon cancer treated with TQ. In my study total GSH
was not affected by TQ. The reason for that could be because GPX catalyzes other
reactions and did not affect total GSH levels. Also it could be specific to colon cancer,
not to mammary cancer.

TQ has been reported to enhance the performance of other cancer drugs. EffenbergerNeidnicht and Schobert (2011) investigated the influence of TQ on side effects exerted
by doxorubicin (drug used for cancer) in human cancer cells. TQ improved the anticancer
properties of doxorubicin in a cell line-specific manner. Effenberger-Neidnicht and
Schobert found significantly more growth inhibition by doxorubicin in combination with
TQ. However, in my study TQ did not decrease the 8-OHdG caused by TAM in the
TAM+TQ treated rats. That could be because at the cellular level it is easier to see the
effect of TQ on cancer cells compared with normal cells. In my study I evaluated the 8OHdG and GSH in the whole body. Future studies are needed to determine the effect of
TQ combined with TAM at a cellular level on 8-OHdG and GSH.
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Both groups treated with TAM gained less weight than rats in the other three groups.
In contrast the TQ group did not differ from the control and DMBA groups. This
indicated that TAM was reducing growth in rats. However, TQ did not reduce growth by
itself but did not prevent the failure of weight gain caused by TAM in TAM+TQ treated
group. According to Otis Brawley (2009), chief medical officer in the American Cancer
Society, about 10 % of women taking TAM report unexpected weight gain. However, the
psychological factor plays an important role in human weight gain. In my study I showed
that TAM causes reduced weight gain after 10 weeks of treatment in female rats. In
contrast, TQ did not affect weight gain like TAM, but did not reduce the effect of TAM
in TAM+TQ treated rats.

Conclusion
The purpose of my study was to determine the role of thymoquinone in improving 8OHdG and GSH compared with tamoxifen in DMBA treated female Sprague-Dawley
rats. Another purpose was to investigate whether TQ could reverse a negative effect of
TAM. My study showed that that 8-OHdG was significantly higher in TAM group
compared with the TQ (P <0.001), the control (P= 0.008) and the DMBA (P=0.041)
groups. Therefore, TQ could be a better anticancer drug than TAM because it decreases
8-OHdG. Moreover, both TAM and TQ appeared to protect the rats from mammary
changes. On the other hand, total GSH did not differ among the groups (P=0.7). In
addition, TQ did not reduce growth like TAM. Therefore, TQ was shown to be effective
in protecting from 8-OHdG and growth retardation. Further work is needed to determine
how exactly TQ works on cancer cells and normal cells compared with TAM and other
anticancer drugs on oxidative DNA damage.
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